Azactam
(Aztreonam)ApprovedSmall molecule
This is an antibiotic injection used to treat bacterial infections in various parts of the body, including the lungs, urinary tract, blood, skin, and abdomen. It can also be used to prevent infections before or after surgery. The medication works by killing bacteria that cause these infections.[2] Azactam is currently approved and in use across 4 indications[4].[1]
Azactam is one of 98 small molecule programs targeting Gonorrhea. It is currently in Approved.
4
Indications
13
Total Trials
0
Active Trials
97
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
386 competitors in Cystic Fibrosis
#DrugCompanyPhaseTrials
1Azactam
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Onglyza
AstraZenecaPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Actimmune
HHorizon Therapeutics Ireland DAC
Preclinical
Proair HFA
GGlaxo Dba Glaxosmithkline
Preclinical
Aztreonam Lysine
GileadPreclinical
Tums
OtsukaPreclinical
Feosol
AAuerbach Hematology Oncology Associates P C
Preclinical
Serevent
GGlaxo Dba Glaxosmithkline
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Skin Infection2 trials
Infections2 trials
Cystic Fibrosis2 trials
Adolescent1 trial
5 more indications
Peritonitis1 trial
Regulatory
FDA Approval Timeline[5]
Dec 31, 1986
AZACTAM
NDA NDA050580
May 24, 1989
AZACTAM IN PLASTIC CONTAINER
NDA NDA050632
Feb 22, 2010
CAYSTON
NDA NDA050814
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Azactam drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Aztreonam. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details